Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.17.

Several equities research analysts recently commented on ELAN shares. Stifel Nicolaus upped their target price on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, May 19th. Piper Sandler cut their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Finally, Barclays cut their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th.

Elanco Animal Health Trading Up 3.8%

NYSE ELAN opened at $13.95 on Monday. The business’s 50-day moving average price is $10.90 and its two-hundred day moving average price is $11.39. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $18.80. The firm has a market capitalization of $6.93 billion, a PE ratio of 34.86, a price-to-earnings-growth ratio of 2.50 and a beta of 1.67. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the company posted $0.34 EPS. The business’s revenue was down 1.0% on a year-over-year basis. On average, analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is owned by company insiders.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of ELAN. Spire Wealth Management raised its stake in shares of Elanco Animal Health by 107.4% in the fourth quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock worth $94,000 after purchasing an additional 4,026 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $142,000. Equitable Trust Co. purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $1,524,000. Summit Trail Advisors LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $199,000. Finally, Van ECK Associates Corp raised its stake in shares of Elanco Animal Health by 4.0% in the fourth quarter. Van ECK Associates Corp now owns 944,978 shares of the company’s stock worth $11,444,000 after purchasing an additional 36,239 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.